Development and Validation Phase of Diffusion Tensor Imaging and Arterial Spin Labelling at 3 Tesla Using a Long-term Effort Model Applicable to Skeletal Muscle Characterization.

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02018718

Enrollment

Registered

2013-12-23

Start date

2013-03-31

Completion date

2014-09-30

Last updated

2017-06-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Marathoners

Keywords

Skeletal muscle, Marathon, MRI

Brief summary

The aim of this study is to demonstrate and quantify the micro architecture and micro vascular changes within skeletal muscles after marathon using 3T MRI (diffusion tensor and arterial spin labeling). Apparent diffusion coefficient, fractional anisotropy and flow parameters will be registered before and after the long-distance run on the lower leg. Axial T1 and axial SPAIR sequences will also be applied at the same time.Stress ox and inflammatory markers will be collected in blood and urine samples and compare with both MRI and Near-infrared spectroscopy (NIRS).

Interventions

DEVICEMagnetic Resonance Imaging (MRI)

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

OTHER

Masking

NONE

Eligibility

Sex/Gender

MALE

Age

25 Years to 50 Years

Healthy volunteers

Yes

Inclusion criteria

* Realizing between 2:10 and 4:30 in the marathon.

Exclusion criteria

* Smoker * Subject with medical treatment or with a treatment interrupted for less than 30 days. * Subject with a osteo-articular, cardiovascular, infectious, lung pathology and/or a metabolic chronic pathology. * MRI Contraindication : Claustrophobic subject ; subject with a intra-cranial vascular clip, with a pacemaker, with a neurostimulator or a cochlear implant ; subject with intraocular metallic foreign bodies.

Design outcomes

Primary

Measure	Time frame	Description
Fractional Anisotropy (FA) measure	at 4 days	The measures will be made from sequences echoplanar (EAR), and will be extracted by post-treatment software Siemens untitled Syngo and FSL, allowing a distortions correction.

Secondary

Measure	Time frame
Apparent Diffusion Coefficient (ADC) value	at 4 days

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026